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a6-containing (a6*) nicotinic ACh receptors (nAChRs)
are selectively expressed in dopamine (DA) neurons
and participate in cholinergic transmission. We gen-
erated and studied mice with gain-of-function a6*
nAChRs, which isolate and amplify cholinergic con-
trol ofDA transmission. In contrast togene knockouts
or pharmacological blockers, which show necessity,
we show that activating a6* nAChRs and DA neurons
is sufficient to cause locomotor hyperactivity. a6L9
0S
mice are hyperactive in their homecage and fail to ha-
bituate to a novel environment. Selective activation of
a6* nAChRswith lowdosesof nicotine, by stimulating
DAbut notGABAneurons, exaggerates these pheno-
types and produces a hyperdopaminergic state
in vivo. Experiments with additional nicotinic drugs
show that altering agonist efficacy at a6* provides
fine tuning of DA release and locomotor responses.
a6*-specific agonists or antagonists may, by target-
ing endogenous cholinergic mechanisms in midbrain
or striatum, provide a method for manipulating DA
transmission in neural disorders.
INTRODUCTION
Identification of the relevant nAChRs involved in (1) normal DA
transmission, (2) disorders of the DA system, such as schizo-
phrenia, Parkinson’s disease, and ADHD, and (3) nicotine depen-
dence is a major priority. a6* (* indicates that other subunits may
be present in the pentameric receptor) nAChRs are highly and
selectively expressed in DA neurons, with additional functional
expression in locus coeruleus and retinal ganglion cells (Azam
and McIntosh, 2006; Azam et al., 2002; Champtiaux et al.,
2002; Gotti et al., 2005b; Le Novere et al., 1996). a6* nAChRs
are selectively inhibited by the marine cone snail peptide
a-conotoxin MII (aCtxMII) (Cartier et al., 1996; Whiteaker et al.,2000). Immunoprecipitation and aCtxMII-binding studies dem-
onstrated that a6b2b3* and a6a4b2b3* pentamers are the pre-
dominant a6* nAChRs in striatum (Champtiaux et al., 2003; Zoli
et al., 2002). a6b2* receptors account for30% of nicotine-stim-
ulated DA release in striatum (Grady et al., 2002; Kaiser et al.,
1998; Kulak et al., 1997). b3 subunits are encoded by a gene
adjacent toChrna6, are usually coexpressed with a6, and are es-
sential for a6* nAChR biogenesis and function (Cui et al., 2003;
Gotti et al., 2005a). a6* receptors exhibit the highest known sen-
sitivity to nicotine and ACh in functional measurements on native
receptors (Salminen et al., 2004) yet function poorly in heterolo-
gous expression systems (Drenan et al., 2008). As a result, there
has been little progress in defining selective agonists for a6*
nAChRs or on other functional measurements. Furthermore, in
midbrain DA neurons, studies of somatodendritic a6* receptors
are complicated by the presence of a4b2* (non-a6), and selec-
tive antagonists of a4b2* (non-a6) have not been identified.
Many experiments with selective destruction of DA neurons
show that the activity of such neurons is necessary for reinforce-
ment of natural and artificial rewards. These cells exhibit tonic
and phasic firing patterns (Grenhoff et al., 1986), where phasic
or ‘‘burst’’ firing carries salient information thought to predict
imminent reward status (Schultz, 2002). Pedunculopontine
tegmentum (PPTg) and laterodorsal tegmentum (LDTg) fibers
provide a cholinergic drive that strongly regulates DA neuron ex-
citability and the transition to burst firing (Lanca et al., 2000).
Midbrain nAChRs in three locations respond to mesopontine-
derived ACh: (1) a7* nAChRs on glutamatergic terminals from ce-
rebral cortex, (2) a4b2* nAChRs on GABAergic terminals and cell
bodies, and (3) a4* and a6* somatodendritic nAChRs on DA neu-
rons (Calabresi et al., 1989). Nicotine interferes with normal cho-
linergic transmission to DA neurons, in part by modifying the
weights of these various nAChR synapses. For example, nicotine
at concentrations found in the CSF of smokers preferentially
desensitizes a4b2* nAChRs regulating midbrain GABA release
(Mansvelder et al., 2002) yet still permits a7* nAChR-regulated
glutamate release (Mansvelder and McGehee, 2000). This
produces both disinhibition and direct excitation of DA neurons,
increasing the probability of a switch to burst firing.Neuron 60, 123–136, October 9, 2008 ª2008 Elsevier Inc. 123
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nAChRs and Cholinergic Control of DA ReleaseNicotine also exaggerates the action of endogenous ACh in
regulating DA release in striatum. Striatal cholinergic interneu-
rons continually release ACh that activates nAChRs, which main-
tains background DA levels during tonic firing of midbrain DA
neurons (Zhou et al., 2001). However, DA release in response
to burst firing of DA neurons is facilitated by a reduction in nAChR
activity (Rice and Cragg, 2004; Zhang and Sulzer, 2004). a6*
receptors, due to their high sensitivity and their selective expres-
sion in DA cell bodies and presynaptic terminals, are probably
key players in cholinergic control of DA release. We reasoned
that genetic ‘‘sensitization’’ of these receptors would (1) amplify
the role of a6* nAChRs in cholinergic control of DA transmission
and (2) allow for selective pharmacological stimulation of these
neurons. This approach would complement previous experi-
ments using a6 knockout mice and a6* pharmacological block-
ade, demonstrating behavioral and physiological responses for
which a6* nAChRs are sufficient.
We introduced a bacterial artificial chromosome (BAC) trans-
gene into the mouse germline with a mutant copy of the mouse
Chrna6 gene that rendered mutant a6* channels ‘‘hypersensi-
tive’’ to endogenous ACh or exogenous nicotine. DA neuron
excitability and DA release is greatly augmented in these mice,
and they exhibit behavioral phenotypes consistent with in-
creased DA neuron firing and/or DA release. These studies
improve our knowledge of cholinergic regulation of the midbrain
DA system and of a6* nAChR biology and have implications for
the treatment of disorders involving changes in DA.
RESULTS
Production and Characterization of BAC a6L9
0S
Transgenic Mice
We selected a 156 kb mouse BAC clone containing the genomic
Chrna6 (a6 nAChR) locus with substantial 50 and 30 flanking
genomic regions for generating a targeting construct to faithfully
recapitulate expression of Chrna6. a6 Leu280 (the Leu 90 residue
in the M2 domain) was mutated to Ser via homologous recombi-
nation using a two-step selection/counterselection procedure in
E. coli. (Figure S1A available online). The final construct was
injected into fertilized mouse eggs, and six transgenic offspring
were identified by genomic DNA sequencing and diagnostic
PCR (Figure S1B and S1C). To eliminate possible artifacts of
transgene position/insertion, we analyzed two independently
derived lines (lines 2 and 5), which have different transgene
copy numbers (Figure S1D) and different genomic positions.
Both mouse lines expressed mutant a6L9
0S mRNA in addition
to wild-type (WT) a6 mRNA (Figure S1E).
We found no difference in location or intensity of [125I]-
a-conotoxin MII (aCtxMII) labeling in a6L9
0S versus WT brains,
confirming correct regional expression of a6* nAChRs in mutant
mice (Figure S1F). To corroborate this, we quantified a6*-binding
sites. Membranes were prepared from striatum (ST), olfactory tu-
bercle (OT), superior colliculus (SC) (regions that account for most
a6*-binding sites), and thalamus (TH) (where most binding sites
are a4b2*). [125I]-epibatidine binding, coupled with inhibition by
unlabeled aCtxMII, revealed a6* and non-a6* (a4b2*) receptors
(Figure S1G). Collectively, these results indicate that a6L9
0S
mice exhibit normal levels and localization of neuronal nAChRs.124 Neuron 60, 123–136, October 9, 2008 ª2008 Elsevier Inc.Spontaneous and Nicotine-Induced Hyperactivity
in a6L9
0S Mice
We measured home cage horizontal locomotor activity for WT
and a6L9
0S mice over a period of 48 hr. a6L9
0S mice were markedly
hyperactive relative to WT control littermates (Figure 1A). This
effect was restricted to lights off (Figure 1B), though there was
a nonsignificant trend toward hyperactivity during lights on.
Although WT mice show locomotor habituation when placed
into a novel environment, a6L9
0S mice exhibit sustained activity.
We measured WT and a6L9
0S locomotor activity for 30 min after
placement in a new home cage environment (Figure 1C). Activity
during the first 15 min of the session was unchanged, but from t =
16 to 30 min, a6L9
0S mice exhibited significantly greater activity
than WT littermates (Figure 1D).
a6* nAChRs are highly expressed in DAergic neurons, and nic-
otine has psychomotor stimulant properties in rodents. We
injected WT and a6L9
0S mice with nicotine and measured loco-
motor activity. Low doses of nicotine (0.15 mg/kg, i.p.) strongly
activated locomotion in a6L9
0S mice but had no effect in WT
mice (Figure 1E). To characterize the locomotor activation phe-
notype in a6L9
0S mice, we constructed a nicotine dose-response
relation. WT mice exhibited locomotor suppression at doses of
nicotine between 0.5 and 2.0 mg/kg, i.p. (Figure 1F), consistent
with previous work (Tapper et al., 2007). In contrast, a6L9
0S
mice exhibited steadily increasing locomotor responses be-
tween 0.02 and 0.15 mg/kg, i.p. nicotine, followed by a decline
at 0.4 mg/kg, i.p and locomotor suppression similar to WT
mice at 1.5 mg/kg, i.p. Thus, selective activation of a6* receptors
results in locomotor activation rather than locomotor suppres-
sion. This phenotype was not a stress response, as saline injec-
tions did not produce locomotor activation (Figure 1G).
Locomotor activation in a6L9
0S mice was dependent on activa-
tion of nicotinic receptors; we noted a strong block of the
locomotor response in a6L9
0S (but not WT) mice preinjected
with mecamylamine (1 mg/kg, i.p.) (Figure 1H). Further, a6L9
0S
locomotor activation acted through dopamine receptors; the
response to 0.15 mg/kg, i.p. nicotine was completely inhibited
by SCH23390 (D1DR antagonist; 2 mg/kg, i.p.) and partially in-
hibited by sulpiride (D2DR antagonist; 20 mg/kg, i.p.) (Figure 1H).
To determine whether a6L9
0S mice develop tolerance or sensi-
tization to nicotine psychomotor stimulation, we injected groups
of a6L9
0S mice once daily for 6 days with nicotine. Injection of
0.02 mg/kg, i.p. or 0.08 mg/kg, i.p. nicotine did not produce
any change in locomotor behavior after repeated injections
(Figure 1I). Nicotine also produces hypothermia in mice, and
a4* hypersensitive mice exhibit this effect at nicotine doses50-
fold lower than WT mice (Tapper et al., 2004). We found no differ-
ence between the hypothermia responses of WT and a6L9
0S mice
(data not shown).
Augmented Nicotine-Stimulated DA Release from
Presynaptic Terminals in a6L9
0S Mice
Mouse a6* nAChRs expressed in midbrain DA neurons are
located both on the cell body and on presynaptic terminals in
caudate/putamen (CPu), nucleus accumbens (NAc), and striatal
aspects of the olfactory tubercle (OT). We measured nicotine-
stimulated [3H]DA release from striatal synaptosomes of WT
and a6L9
0S mice. We made separate tissue samples containing
Neuron
a6
*
nAChRs and Cholinergic Control of DA Releasestriatum (ST; CPu and dorsal aspects of NAc) and olfactory tu-
bercle (OT). Because CPu receives DAergic projections mainly
from substantia nigra whereas OT receives DAergic projections
exclusively from VTA, this preparation crudely separates the
mesostriatal and mesolimbic pathways. For total DA release in
ST, there was no difference in Rmax (Figures 2A and S2) and
Figure 1. a6L9
0S Mice Are Markedly Hyperactive and Hypersensitive to the Psychomotor Stimulant Action of Nicotine
(A and B) a6L9
0S mice are hyperactive in their home cage. Horizontal locomotor activity of mice (a6L9
0S or WT cagemates) in their home cage environment was
recorded during a 48 hr period. Raw locomotor activity data (number of ambulations/15 min period) are reported (A). Total locomotor activity from ‘‘lights on’’ and
‘‘lights off’’ periods indicated in (A) are shown (B) for WT and a6L9
0S mice.
(C and D) a6L9
0S mice do not habituate to a novel environment. Mice (a6L9
0S or WT cagemates) were removed from their home cage and immediately placed in
a fresh cage. Locomotor activity was measured for 30 min. Raw locomotor activity data (number of ambulations/min) are reported (C). Total locomotor activity
from (C) for t = 0–15 min or t = 16–30 min is shown (D).
(E) Nicotine specifically stimulates locomotor activity in a6L9
0S transgenic mice. After 8 min of baseline locomotor activity, mice (WT, a6L9
0S line 2 and 5) were
injected with 0.15 mg/kg i.p. nicotine. Locomotor activity was recorded for an additional 30 min after injection. Raw locomotor activity data (number of
ambulations/min) are reported.
(F) Dose-response relationship for nicotine-stimulated locomotor activity in WT and a6L9
0S mice. Mice were administered nicotine at the indicated dose, and total
locomotor activity was measured as in (E). Locomotor activity for each mouse was normalized to a saline control injection for the same mouse. Data are
expressed as the percentage of the response to saline (set to 100%).
(G) Locomotor activity following saline or nicotine (0.15 mg/kg, i.p.) injection in WT and a6L9
0S mice. Total raw locomotor activity data (number of ambulations/min,
30 min total) are reported.
(H) Behavioral pharmacology of nicotine-stimulated locomotor activation in a6L9
0S mice. Mice (WT or a6L9
0S) were preinjected with saline, mecamylamine
(1 mg/kg, i.p.), SCH23390 (2 mg/kg, i.p.), sulpiride (20 mg/kg, i.p.), prazosin (1 mg/kg, i.p.), or yohimbine (1 mg/kg, i.p.) immediately prior to the start of data
acquisition. Nicotine (0.15 mg/kg, i.p.) was injected a t = 8 min, and locomotor activity was measured for an additional 30 min. Total raw locomotor activity
data (number of ambulations/min, 30 min total) are reported.
(I) Lack of sensitization or tolerance following repeated nicotine administration in a6L9
0S mice. Groups of a6L9
0S mice were injected with saline once daily for
3 consecutive days, followed by nicotine (0.02 mg/kg, i.p., or 0.08 mg/kg, i.p.) once daily for 6 consecutive days. Locomotor activity was measured as in (E),
and nicotine-stimulated locomotor activity for each mouse was normalized to saline control injections (average of three saline injections) for the same mouse.
Data are expressed as the percentage of the response to saline (set to 100%).
All data are expressed as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.Neuron 60, 123–136, October 9, 2008 ª2008 Elsevier Inc. 125
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nAChRs and Cholinergic Control of DA Releasea small but significant reduction in EC50 for both transgenic lines
relative to WT (Figure 2G). In OT, there was a slight increase in
Rmax (Figures 2D and S2) and a greater reduction in the EC50
for a6L9
0S lines compared to WT (Figure 2H). We used aCtxMII
to inhibit a6* receptors, revealing the contribution of a6* and
non-a6* nAChRs to this augmented DA release. In ST and OT,
we observed a significant increase in total DA release mediated
by a6 at most nicotine concentrations (Figures 2B and 2E). Inter-
estingly, this was accompanied by a concomitant decrease in
the non-a6* (a4b2* mediated) component (Figures 2C and 2F)
in a6L9
0S samples. In ST and OT, we measured a significant
reduction in the EC50 for the a6-dependent component and no
Figure 2. Presynaptic a6* nAChRs in Stria-
tumMediate Hypersensitive, Nicotine-Stim-
ulated DARelease in a6L9
0S TransgenicMice
(A–C) Hypersensitive DA release in striatum of
a6L9
0S transgenic mice is a6* dependent. Striata
(‘‘ST’’; dorsal striatum and dorsal aspects of
nucleus accumbens) from WT and a6L9
0S mice
were dissected and synaptosomes were pre-
pared. DA release was stimulated with a range of
nicotine concentrations (3 nM, 10 nM, 30 nM,
100 nM, 300 nM, 1 mM, 10 mM), and a concentra-
tion-response relation for each mouse line (n =
6 mice/line) is shown for total release (A). To deter-
mine the relative contribution of a6* and non-a6*
receptors, striatal synaptosome samples were
incubated with aCtxMII (50 nM). a6*-independent
release is shown in (C), and aCtxMII-sensitive
(a6* dependent) release is shown in (B).
(D–F) Hypersensitive DA release in olfactory tuber-
cle of a6L9
0S transgenic mice is a6* dependent.
Olfactory tubercle (‘‘OT’’) was dissected from WT
and a6L9
0S mice, and samples were processed
as in (A)–(C).
(G and H) Quantification of hypersensitive DA
release in striatum (G) and olfactory tubercle (H).
Average nicotine EC50 values for each concentra-
tion-response curve from (A)–(F) are shown.
(I–K) a6* nAChRs do not participate in nicotine-
stimulated GABA release in striatum. ST and OT
were dissected and combined, followed by synap-
tosome preparation. GABA release was stimu-
lated by nicotine at the following concentrations:
100 nM, 300 nM, 1 mM, 3 mM, 10 mM, 30 mM,
100 mM, and 300 mM. Total (I) release and aCtxMII-
sensitive (J) and resistant (K) components are
shown.
Data are expressed as mean ± SEM. *p < 0.05.
change in EC50 for the non-a6 component
(Figures 2G and 2H). Overall, DA release
from a6L9
0S striatal synaptosomes may
be underestimated by this assay, as
20 mM K+ stimulated slightly less DA
release in both a6L9
0S lines relative to WT
mice (Figure S2). These results directly
reveal that selective a6* activation is
capable of stimulating striatal DA release.
a4b2* nAChRs modulate striatal GABA
release (Lu et al., 1998). We measured
GABA release from striatal (ST and OT combined) synaptosomes
of WT and a6L9
0S mice to determine whether any a6*-dependent
component was revealed by the gain-of-function L90S mutation.
There was no difference in total GABA release for any genotype
comparison (Figures 2I and S3), and there was no a6* compo-
nent (Figures 2J, 2K, and S3). A Student’s t test on Rmax and
EC50 values revealed no significant difference between total
and aCtxMII-resistant GABA release for any genotype (WT
Rmax p = 0.47, WT EC50 p = 0.73; line 2 Rmax p = 0.93, line
2 EC50 p = 0.31; line 5 Rmax p = 0.62, line 5 EC50 p = 0.63).
Furthermore, there was no significant difference between any
genotype on Rmax or EC50 (two-way ANOVA with Tukey post126 Neuron 60, 123–136, October 9, 2008 ª2008 Elsevier Inc.
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nAChRs and Cholinergic Control of DA Releasehoc comparison: Rmax F(2,66) = 1.87, p = 0.163; EC50 F(2,66) =
0.744, p = 0.48) nor was there any effect of aCtxMII across all
genotypes on Rmax or EC50 (Rmax F(1,66) = 0.35, p = 0.554; EC50
F(1,66) = 0.643, p = 0.426). Stimulation with 20 mM K
+ showed
no differences between WT and a6L9
0S samples for GABA
release (Figure S3). This indicates that GABAergic terminals in
striatum, either derived locally or from VTA or SNr GABAergic
neurons, contain no appreciable a6* nAChRs.
a6* receptors synthesized in retinal ganglion cells reside in the
superficial layers of superior colliculus (SC) (Gotti et al., 2005b),
and we measured nicotine-stimulated 86Rb+ efflux from SC syn-
aptosomes. a6L9
0S SC aCtxMII-sensitive receptors are hyper-
sensitive to nicotine relative to WT, whereas aCtxMII-resistant
86Rb+ efflux is unchanged (Figure S4).
DA Release and Locomotor Activity Are Precisely
Controlled by Varying a6* Agonist Efficacy
The DA release data suggest a mechanism involving dopamine
for the psychomotor stimulant action of nicotine as well as the
spontaneous hyperactivity observed. For DA release in WT
mice, TC 2429 (Figure 3A) (Bhatti et al., 2008) is a full agonist (ver-
sus nicotine) with 3-fold selectivity at a6b2* and a weak partial
agonist at a4b2, whereas TC 2403 (Figure 3E) (Bencherif et al.,
1996; Lippiello et al., 1996) is a full agonist (versus nicotine) at
Figure 3. a6-Dependent Neurotransmitter Release and Behavioral Phenotypes Are Discriminated by Subtype-Selective Nicotinic
Compounds
(A) TC 2429 structure.
(B–D) An a6*-selective nicotinic agonist demonstrates enhanced striatal DA release in a6L9
0S mice. Striatum (ST) and olfactory tubercle (OT) from WT and a6L9
0S
mice were dissected and combined, followed by synaptosome preparation. DA release was stimulated with a range of nicotine concentrations (see Figure 2A),
and total (B) release as well as aCtxMII-sensitive (C) and aCtxMII-resistant (D) components are shown for each genotype.
(E) TC 2403 structure.
(F–H) An a4*-selective nicotinic agonist modestly activates striatal a6* nAChRs in a6L9
0S mice. Similar to (B)–(D), total DA release (F) as well as aCtxMII-sensitive
(G) and aCtxMII-resistant (H) components are shown for TC 2403.
(I) An a6*-selective agonist stimulates locomotor activity in a6L9
0S mice without affecting WT activity. Mice were administered TC 2429 at the indicated dose, and
total locomotor activity was measured as in Figure 1. Locomotor activity for each mouse was normalized to saline control injections in the same mouse.
(J) a6* nAChR stimulation by TC 2403 induces modest locomotor activity in a6L9
0S mice. Mice were administered TC 2403 at the indicated dose, and total
locomotor activity was measured as in Figure 1. Locomotor activity for each mouse was normalized to saline control injections in the same mouse.
(K) Close correlation between a6*-mediated DA release and locomotor activity. For nicotine (Figure 2), TC 2429, and TC 2403, aCtxMII-sensitive DA release
average Rmax values for lines 2 and 5 (ST and OT combined) were plotted versus peak locomotor activity (percentage above 100). A regression line (R
2 = 0.995)
for the three compounds is shown.
Data are reported as mean ± SEM.Neuron 60, 123–136, October 9, 2008 ª2008 Elsevier Inc. 127
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nAChRs and Cholinergic Control of DA Releasea4b2 and has no activity at a6b2* (Figure S5). TC 2429, like nic-
otine, was more efficacious and more potent for DA release from
striatal synaptosomes of a6L9
0S mice relative to WT (Figure 3B). In
both a6L9
0S lines, Rmax was greater, and the EC50 was reduced
relative to WT. This was entirely attributable to a6* nAChRs
(Figure 3C), which accounted for a greater proportion of the total
response. There was a concomitant decline in the total response
but not the EC50 for a4b2* (aCtxMII resistant) nAChRs (Fig-
ure 3D). We characterized the ability of TC 2429 to induce
psychomotor activation in a6L9
0S and WT control mice. Similar
to nicotine, injections of TC 2429 stimulated locomotor activity
in a6L9
0S mice but not WT (Figure 3I). Unlike nicotine, TC 2429
did not produce locomotor suppression in WT mice.
TC 2403 was slightly more potent and had equivalent efficacy
for DA release in a6L9
0S versus WT striatum (Figure 3F). The
increased potency was due to the amplification of an aCtxMII-
sensitive response not visible in WT tissue preparations (Fig-
ure 3G). TC 2403 was a partial agonist at this receptor (Figure S5).
Consistent with competition between a6 and a4 subunits for
common b2 subunits, there was a decline in Rmax in a6
L90S
mice for a4b2* (aCtxMII resistant) nAChRs (Figures 3H and S5).
In locomotor assays, TC 2403 induced a slight locomotor activa-
tion in a6L9
0S but not WT mice (Figure 3J), consistent with partial
activity at a6* nAChRs. Nicotine (10 mM) was used as a positive
control for DA release for TC 2429 and TC 2403 (Figure S5). For
nicotine, TC 2429, and TC 2403, we noted a tight correlation
between a6*-dependent DA release in vitro and peak locomotor
activity in vivo (Figure 3K). These results suggest a mechanism
whereby agonism at a6* nAChRs stimulates striatal DA release
and produces locomotor stimulation, perhaps without GABAergic
attenuation, which is normally coactivated by a4b2* activation
(Figures 2I–2K).
a6L9
0S Receptors Sensitize DA Neurons to Activation
by Nicotine
To directly determine whether DA neurons in a6L9
0S mice express
hypersensitive a6* nAChRs, we prepared coronal midbrain slices
(Figure 4A) and made patch-clamp recordings from VTA DA neu-
rons in whole-cell configuration. DA neurons can be identified
based on expression of tyrosine hydroxylase (TH) (Figure 4B)
and with electrophysiology (Wooltorton et al., 2003); DA neurons
exhibit pacemaker firing (1–5 Hz), membrane potential adapta-
tions in response to hyperpolarizing current injections, and often
express Ih. We recorded currents induced by local nicotine appli-
cation (Figure 4C) at a range of concentrations. Nicotinic cur-
rents in a6L9
0S neurons were markedly hypersensitive to nicotine;
puffs of nicotine (1 mM) elicited inward currents that were larger
than those seen in WT neurons at any concentration (Figure 4D).
At all nicotine concentrations, a6L9
0S neurons of both transgenic
lines showed larger average peak current responses than WT
neurons (Figure 4E). Normalizing the peak current amplitude to
cell capacitance yielded identical results (Figure S6).
Whole-cell responses to 1 mM nicotine were R90% blocked
when aCtxMII (100 nM) was added to the perfusate (Figure 4F,
upper panel). aCtxMII block persisted 30 min after washout,
consistent with previous work (McIntosh et al., 2004). Likewise,
responses to 1 mM nicotine were 100% blocked in the presence
of dihydro-b-erythroidine (DHbE, 2 mM), a potent inhibitor of most128 Neuron 60, 123–136, October 9, 2008 ª2008 Elsevier Inc.b2* receptors (Figure 4F, lower panel). Although the general
kinetics of these hypersensitive responses suggests that a6L9
0S
receptors are postsynaptic, a presynaptic mechanism is not ex-
cluded by the data. To address this, we inhibited AMPA/kainate
receptors with 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX,
15 mM) and voltage-gated Na+ channels with tetrodotoxin (TTX,
0.5 mM). Inward current responses to 1 mM nicotine were
unaffected by either CNQX or TTX (Figure 4G). Furthermore,
we found no effect (n = 6, 0% block) on peak current amplitude
(1 mM nicotine) in the presence of methyllycaconitine (MLA,
10 nM) (Figure 4G). Thus, hypersensitive a6* responses were
consistent with a postsynaptic mechanism.
VTA DA neuron pacemaker firing was unaltered in WT versus
a6L9
0S slices (Figure 4I). To determine whether hypersensitive
nicotinic receptors in a6L9
0S neurons were capable of acutely
altering the excitability of VTA DA neurons, we recorded action
potential firing in response to local nicotine application. Nicotine
(1 mM) induced a transient increase in the instantaneous firing
rate and a depolarization of the membrane potential (Figure 4H).
There was a significant increase in the firing rate for a6L9
0S but not
WT cells (Figure 4I).
We noticed greater fluctuations in the holding current in a6L9
0S
VTA DA neurons than in WT (Figure 5A). This suggests that some
a6L9
0S channels are tonically active, reminiscent of previous
observations in a4 nAChR L90S and L90A knockin mice (Labarca
et al., 2001; Shao et al., 2008). To determine whether this change
in resting membrane conductance was due to active a6L9
0S
channels, a6* receptors were blocked by application of aCtxMII.
a6 blockade completely eliminated this increased channel noise
in all a6L9
0S cells tested (Figure 5B). WT neurons bathed in
aCtxMII served as a control (Figure 5C). To quantify this, we
measured the root-mean-square (RMS) value of the fluctuations
in WT and a6L9
0S voltage-clamp recordings. There was a signifi-
cant decrease in the noise for a6L9
0S cells in the presence of
aCtxMII (Figure 5D). We found no effect of CNQX, picrotoxin, or
TTX on the increased membrane noise in a6L9
0S cells (Figure S7).
DHbE, however, completely eliminated the increased noise sim-
ilar to aCtxMII (Figure S7). These results further demonstrate that
VTA DA neurons express functional, hypersensitive a6* nAChRs
and that these receptors may be activated by local ACh.
We examined the properties of hypersensitive a6* receptors in
DA neurons of the substantia nigra pars compacta (SNc) and
found similar results to the VTA. SNc DA neurons from a6L9
0S
mice expressed hypersensitive nicotinic currents relative to
WT, and firing rates were excited by 1 mM nicotine in a6L9
0S but
not WT cells (Figures S8A and S8B). Finally, a6L9
0S SNc DA neu-
rons expressed tonically active, aCtxMII-sensitive a6* receptors
(Figure S8C).
Selective Expression of Functional a6* Receptors
in Midbrain DA Neurons
Although expression data suggest selective expression of a6*
nAChRs in DA neurons, no electrophysiological experiments
supporting this idea have been published. Midbrain DA neurons
typically express D2-class autoreceptors, in contrast to midbrain
GABAergic neurons (Nashmi et al., 2007). We recorded from 15
VTA neurons, ten of which expressed a6* nAChRs (based on
large inward current responses to 1 mM nicotine) and five which
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nAChRs and Cholinergic Control of DA Releasedid not. All cells expressing a6* nAChRs were sensitive to the
inhibitory properties of the D2 DA receptor agonist quinpirole
(Figure 6A, panel i), indicating that these cells were likely
DAergic. In contrast, most a6*-negative cells did not express
D2 receptors (Figure 6A, panel ii). To more accurately determine
whether a6* receptors are functionally expressed in DA and/or
GABA cells in midbrain, we recorded from substantia nigra
(SN) neurons in slices from WT and a6L9
0S mice. The spatial par-
titioning of DA and GABA neurons in the SN pars compacta (SNc)
and pars reticulata (SNr) (Figure 6B, panel i) was combined with
Figure 4. Ventral Tegmental Area DA Neurons Express Hypersensitive nAChRs
(A) Diagram of coronal sections from mouse brain containing ventral tegmental area (Franklin and Paxinos, 2008).
(B) Tyrosine hydroxylase (TH) staining of DA neurons in coronal slices. Coronal slices (250 mm; bregma3.1 mm) from an a6L90S mouse were fixed and stained for
TH as described in Supplemental Experimental Procedures. The boxed area from (A) is shown. Scale bar: 350 mm.
(C) Micrograph of VTA neuron studied with local nicotine application. A VTA neuron is recorded via the patch pipette (right), and the cell body is stimulated with
a nicotine-filled micropipette (left). Scale bar: 20 mm.
(D) Hypersensitive nAChRs in VTA neurons. Patch-clamp recordings were taken from VTA DA neurons in coronal slices from a6L9
0S and WT mice. Neurons were
voltage clamped at 60 mV, and nicotine at the indicated concentration was locally applied to the cell body using a picospritzer (250 ms). Except during drug
application, the micropipette tip was kept several hundred microns from the cell to prevent receptor desensitization. Scale bars: 200 pA, 5 s.
(E) Concentration-response relationship for hypersensitive nicotinic responses in WT and a6L9
0S mouse lines. The average peak amplitude of the cellular response
for each mouse line and each nicotine concentration is plotted.
(F) Hypersensitive nAChRs are inhibited by aCtxMII and dihydro-b-erythroidine (DHbE). Nicotine (1 mM) was locally applied to VTA DA neurons in a6L9
0S slices
before (black trace) and after (red trace) 10 min bath application of aCtxMII (100 nM) or DHbE (2 mM) (n = 5 for each antagonist). Scale bars: 100 pA, 3 s.
(G) Hypersensitive nAChR activation is independent of AMPA receptor function, action potentials, and a7* nAChRs. The indicated drug was bath applied to VTA
DA neurons in a6L9
0S slices, followed by activation of nAChRs with local application of 1 mM nicotine. Peak current amplitudes in the presence of 6-cyano-7-nitro-
quinoxaline-2,3-dione (CNQX), tetrodotoxin (TTX), or methyllycaconitine (MLA) were unchanged. Results from both mouse lines were identical in all cells tested
(n = 3 for each drug). Scale bars: (Gi) 100 pA, 3 s; (Gii) 60 pA, 3 s; (Giii) 70 pA, 3 s.
(H) Dopamine neuron firing is augmented by a low nicotine concentration only in a6L9
0S mice. VTA dopamine neurons were held in I = 0 mode, and nicotine (1 mM)
was puff applied (arrow) as in (D) following a stable recording of baseline firing. A representative firing response is shown for a neuron from each genotype. Scale
bars: 100 mV, 2 s.
(I) Quantification of firing responses in WT and a6L9
0S VTA DA neurons. Peak instantaneous firing frequency values for each nicotine (1 mM) application (one per
cell) were derived and averaged for each mouse line. Average peak values are compared with the average baseline firing rate for the same group of cells.
Data are reported as mean ± SEM. *p < 0.05, ***p < 0.001.Neuron 60, 123–136, October 9, 2008 ª2008 Elsevier Inc. 129
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nAChRs and Cholinergic Control of DA Releaseelectrophysiological signatures (Figure 6B, panels ii–iv; see Ex-
perimental Procedures) to unambiguously identify these cell
types. In whole-cell recordings from a6L9
0S and WT SN neurons,
we observed hypersensitive nicotinic responses in a6L9
0S DA
neurons, but not in GABA neurons (Figure 6C). Average peak
current amplitudes were comparable between a6L9
0S lines 2
and 5 in SNc DA neurons (Figure 6D, panel i). Average responses
in WT and a6L9
0S GABA neurons were%10 pA (Figure 6D, panel
ii). Responses to nicotine at 1 mM were undetectable in WT DA
and GABA neurons (Figure 6C, panel i); however, these cells
responded predictably to 100 mM or 1 mM nicotine (data not
shown). As a control for the specificity of our results, we
recorded from SNc and SNr neurons in slices from a4L9
0A mice.
We found hypersensitive nicotinic responses in SNc and SNr
neurons from these mice (Figures 6C and 6D), consistent with
the idea that a4 is expressed in both DA and GABA cells (Nashmi
et al., 2007). These results, coupled with the absence of a6* re-
ceptors in GABAergic presynaptic terminals in striatum (Figures
2I–2K), indicate that functional a6* receptors, in contrast to a4*
receptors, are restricted to DA neurons in the midbrain.
The results thus far suggest increased DA tone in midbrain
and/or striatum. To examine this, we studied pacemaker and
nicotine-induced firing of VTA DA neurons in the absence and
presence of sulpiride, a D2 DA receptor antagonist. There was
no change in the ability of sulpiride to modestly increase baseline
firing between WT and a6L9
0S VTA DA cells (Figure S9). Further,
sulpiride did not affect 1 mM nicotine-induced increases in firing
in a6L9
0S cells or its lack of effect in WT cells (Figure S9). To de-
termine whether augmented striatal DA release in a6L9
0S mice
(Figure 2) could be detected in brain slices using patch-clamp re-
cordings, we studied striatal cholinergic interneurons. These
cells are readily identifiable (Figure S10A), their activity is modu-
lated by DA, and they are the source of ACh that activates a6* re-
ceptors on presynaptic DA terminals. We detected no change in
spontaneous firing between WT and a6L9
0S cells (Figure S10B).
The resting membrane potential for a6L9
0S line 2 (but not line 5)
was hyperpolarized compared to WT (Figure S10C). Although
DA may modulate Ih currents in cholinergic interneurons (Deng
et al., 2007), we found no difference between WT and a6L9
0S Ih
expression or function in these cells (Figures S10D and S10E).
a6L9
0S nAChRs in Locus Coeruleus Neurons Do Not
Account for Behavioral Phenotypes in Mutant Mice
To determine whether a6* activation in a6L9
0S mice might also
stimulate locus coeruleus (LC) neuron firing, we recorded from
LC neurons in coronal slices from WT and a6L9
0S mice (Figure 7A).
LC neurons express tyrosine hydroxylase (TH) (Figure 7B), ex-
hibit spontaneous firing (1–2 Hz; Figure 7C, panel i), and lack Ih
(Figure 7C, panels ii and iii). LC neurons from a6L9
0S mice
exhibited larger responses to locally applied nicotine compared
to WT cells and cells from a4L9
0A knockin mice (Figures 7D and
7E). Although these responses were sensitive to aCtxMII (Fig-
ure 7F) and therefore a6 dependent, they were smaller
and 10-fold less sensitive to nicotine than were receptors on
VTA DA neurons (compare Figures 4E and 7E). LC neurons
were also able to fire action potentials in response to nicotine
(Figure 7G), but at concentrations of nicotine 10-fold higher
than for DA neurons (Figure 7H). The reduced sensitivity of LC
a6* nAChRs relative to receptors on DA neurons suggests that
they do not participate in the psychostimulant response to nico-
tine that we observed. In support of this, we found no change in
the locomotor response to nicotine when prazosin (a1AR antag-
onist) or yohimbine (a2AR antagonist) were administered prior to
challenge with nicotine (Figure 1H).
DISCUSSION
a6L9
0S Mice Reveal a Role for a6* nAChRs in Cholinergic
Modulation of DA Transmission
Here, we report several new aspects of a6* nAChR biology and
its role in cholinergic regulation of DA transmission. Also, we
show the behavioral effects of selectively activating DA neurons
Figure 5. Spontaneous a6 Channel Activity
in a6L9
0S VTA DA Neurons
(A) Increased current fluctuations in voltage-clamp
recordings from a6L9
0S neurons. VTA DA neurons
from WT or a6L9
0S mice were voltage clamped
at 60 mV. A segment from a representative
voltage-clamp recording is shown. Scale bars:
40 pA, 0.8 s.
(B) Noise in a6L9
0S neurons is dependent on a6*
nAChRs. VTA DA neurons were voltage clamped
at 60 mV, and a baseline recording was taken
(control). aCtxMII was bath applied for 10 min,
and a representative (n = 4, each line) segment
of the voltage-clamp record after this 10 min pe-
riod is shown (+aCtxMII, 100 nM) for the same cell.
(C) aCtxMII inhibition has no effect in WT control
recordings. As a negative control for perfusion
artifacts, WT neurons were assayed as in (B).
(D) Quantification of channel noise increase in
a6L9
0S mice. RMS noise values for voltage-clamp
recordings from VTA DA neurons in the presence
and absence of aCtxMII are shown.
Data are reported as mean ± SEM. *p < 0.05. Scale
bars (B and C): 20 pA, 0.5 s.130 Neuron 60, 123–136, October 9, 2008 ª2008 Elsevier Inc.
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nAChRs and Cholinergic Control of DA Release(Figure 1). Our electrophysiology and neurochemistry experi-
ments reveal a major role for a6* nAChRs in regulating both DA
neuron firing (Figures 4 and S8) and synaptic release of DA in
the striatum (Figures 2 and 3). Our finding that a6* nAChRs are
largely excluded from midbrain GABA neurons (Figure 6) and
from striatal GABAergic terminals (Figures 2I–2K), in stark con-
trast to a4b2* nAChRs, is sustained by our behavioral data sug-
gesting relatively unrestrained DA transmission in a6L9
0S mutant
mice. We propose a model in which specific functional expres-
sion of high-sensitivity a6L9
0S nAChRs in DA neurons renders
these cells selectively hypersensitive (Figure S11) to activation
by endogenous ACh (Figure 8B) or by exogenous nicotine
(Figure 8D). This likely reflects that, in WT mice or in humans,
high-affinity a6* nAChRs are specifically poised to modulate
the activity of monoamine neurotransmitters such as DA. These
studies provide long-sought sufficiency data for a6* nAChRs,
complementing studies utilizing a6* loss-of-function mutations
and pharmacological blockade.
In Vivo a6* nAChR Stoichiometry and Biophysical
Properties Revealed by a6L9
0S Mice
We observed similar levels of aCtxMII binding in a6L9
0S brains
compared to WT controls (Figures S1F and S1G). This is interest-
ing in light of the fact that the two a6L9
0S lines harbor multiple
copies of the transgene (Figure S1D). Unlike an exon-replace-
ment knockin approach, a6L9
0S BAC transgenic mice retain two
copies of WT Chrna6. In DA neurons, a6 and a4 subunits com-
pete for common, limiting nAChR subunits such as b2, possibly
b3 and a5, and probably for unknown assembly factors or chap-
erone proteins that may be specific to this cell type. As a result,
Figure 6. Functional a6* nAChRs Are Selectively Expressed in Midbrain DA, but Not GABA, Neurons
(A) VTA DA neurons expressing hypersensitive a6* nAChRs express dopamine D2-class autoreceptors. VTA DA neurons expressing a6L9
0S nAChRs were iden-
tified by the presence of large (>100 pA) inward nicotinic currents similar to Figure 4. Following nicotine application, cells were held in I = 0 mode, and quinpirole
(QP; 1 mM) was bath applied. Action potential firing in response to QP is shown for a representative neuron expressing (panel [Ai]; n = 10/10) or not expressing
(panel [Aii]; n = 4/5) a6L9
0S receptors.
(B) Identification of substantia nigra (SN) DA and GABA neurons. A diagram of coronal sections (bregma 3.1 mm) from mouse brain containing SN pars
compacta (SNc) and pars reticulata (SNr) is shown (Franklin and Paxinos, 2008). SN DA versus GABA neurons were identified by (Bi) location: SNc contains
DA neurons whereas SNr is largely GABAergic; (Bii) DA neurons express hyperpolarization-activated cation current (Ih); (Biii) DA neurons exhibit pacemaker firing
(1–5 Hz), whereas GABA neurons fire at >10 Hz; (Biv) DA neurons have broad spikes (>2 ms), whereas GABA neurons have narrow (%1 ms) spikes. Scale bars: (Bii)
400 pA (current traces)/30 mV (voltage step), 0.5 s; (Biii) 50 mV, 1 s; (Biv) 50 mV, 1 ms.
(C) Hypersensitive a6* nAChRs reveal selective expression in DA neurons. SN DA and GABA neurons were identified according to criteria in (B). Neurons in slices
from WT, a6L9
0S, and a4L9
0A mice were patch clamped in whole-cell configuration, and nicotine (1 mM) was locally applied (arrow) to activate hypersensitive
nAChRs. Representative recordings for each are shown. Scale bars: (WT and a6L9
0S) 100 pA, 5 s; (a4L9
0A) 200 pA (DA)/80 pA (GABA), 5 s.
(D) Quantification of current amplitudes from (C). Average peak current amplitude in response to 1 mM nicotine for each genotype and cell type is shown.
Data are expressed as mean ± SEM.Neuron 60, 123–136, October 9, 2008 ª2008 Elsevier Inc. 131
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nAChRs and Cholinergic Control of DA Releasethe level of functional a6* expression in a6L9
0S neurons is deter-
mined by a competition between WT and L90S a6 subunits.
Indeed, for every agonist tested, we observed diminished peak
aCtxMII-resistant (a4b2* dependent) DA release in a6L9
0S ST/
OT (Figures 2 and 3) despite equal levels of a4b2*-binding sites
(Figure S1G). Future crosses of a6L9
0S mice to a4, b2, and b3
nAChR heterozygous or homozygous KO mice will yield further
insights into nAChR subunit stoichiometry in vivo.
We noted a large increase in the potency and efficacy of nico-
tine in whole-cell recordings from a6L9
0S DA neurons (Figures 4D
Figure 7. Modest Hypersensitivity to Nicotine at a6L9
0S nAChRs in Noradrenergic Locus Coeruleus Neurons
(A) Diagram of coronal sections (bregma 5.4 mm) containing locus coeruleus (Franklin and Paxinos, 2008).
(B) Tyrosine hydroxylase (TH) staining of NE neurons in coronal slices. Coronal slices (200 mm; bregma 5.4 mm) from an a6L90S mouse were fixed and stained for
TH as described in Supplemental Experimental Procedures. The boxed area from (A) is shown. Scale bar: 100 mm. MPB, medial parabrachial nucleus; LC, locus
coeruleus; Bar, Barrington’s nucleus; LDTg, laterodorsal tegmental nucleus; 4V, fouth ventricle.
(C) Electrophysiological identification of LC neurons. LC neurons are identified by (Ci) pacemaker firing at 1–2 Hz, (Cii) lack of Ih, and (Ciii) lack of membrane
potential ‘‘sag’’ for hyperpolarizing current pulses (responses shown for injection of 80, 40, and +20 pA). Scale bars: (Ci) 70 mV, 1.5 s; (Cii) 150 pA,
350 ms; (Ciii) 70 mV, 500 ms.
(D) Hypersensitive nicotinic responses in LC neurons. Patch-clamp recordings were taken from LC neurons in coronal slices from WT, a4L9
0A, and a6L9
0S mice.
Neurons were voltage clamped at 60 mV, and nicotine at the indicated concentration was locally applied (arrow) to the cell body (250 ms).
(E) Concentration-response relationship for hypersensitive nicotinic responses in WT, a4L9
0A, and a6L9
0S mice. The average peak amplitude of the cellular
response for each mouse line and each nicotine concentration is plotted.
(F) Hypersensitive a6L9
0S nAChRs are inhibited by aCtxMII. Nicotine (10 mM) was locally applied (arrow) to LC neurons in a6L9
0S slices before and after 10 min bath
application of aCtxMII (100 nM) (n = 3). Scale bars: 50 pA, 4 s.
(G) Noradrenergic neuron firing is augmented by a moderate nicotine concentration only in a6L9
0S mice. Following a stable recording of baseline action potential
firing, nicotine (10 mM) was puff applied (arrow) as in (D). Exemplar responses are shown for a WT and a6L9
0S neuron. Scale bars: 70 mV, 3 s.
(H) Quantification of firing responses in WT and a6L9
0S LC neurons. Peak instantaneous firing frequency values for each nicotine concentration were derived and
averaged. Average peak values are compared with the average baseline firing rate (0 mM nicotine) for the same group of cells.
Data are reported as mean ± SEM. **p < 0.01.132 Neuron 60, 123–136, October 9, 2008 ª2008 Elsevier Inc.
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nAChRs and Cholinergic Control of DA Releaseand 4E). With respect to nicotinic channel engineering, the pres-
ent studies are analogous to electrophysiological and Ca2+ flux-
based measurements of hypersensitive nicotinic responses in
a4L9
0S, a4L9
0A, and a7L9
0T knockin mice (Fonck et al., 2005; Lab-
arca et al., 2001; Tapper et al., 2004; Wooltorton et al., 2003). The
augmented responses (increased efficacy) to agonist likely re-
flect an increased maximal probability of channel opening, Popen,
conferred by the L90S mutation (Labarca et al., 1995), while the
increased potency results from this mutation shifting the agonist
concentration-response relation to lower concentrations (Revah
et al., 1991). The increased noise in voltage-clamp recordings
from a6L9
0S neurons probably arises from one of two effects:
(1) the presence of ACh in the slice preparation that is secreted
from terminals of severed mesopontine cholinergic axons or (2)
unliganded openings. Future in vivo studies, such as recordings
from awake, behaving animals, will help confirm whether a6L9
0S
mouse spontaneous behavioral phenotypes are caused by the
former or the latter.
Contrasting Cell-Specific Expression of a4* versus a6*
nAChRs Leads to Behavioral Differences in a4
and a6 Gain-of-Function Mutant Mice
a6L9
0S mice are viable and fertile, whereas full expression of
a4L9
0S* receptors causes neonatal lethality due to excitotoxic
death of DA neurons (Labarca et al., 2001). This could be due
to differential expression of a4 and a6 in development; unlike
a4 expression, peak a6 expression occurs well after birth
(Azam et al., 2007). It is also possible that a6L9
0S* receptors are
comparatively insensitive to activation by choline at concentra-
tions found in CSF.
In the mesostriatal and mesolimbic DA system, a4b2* nAChRs
are expressed in DA neuron cell bodies, dendrites, and axon
terminals, as well as in cell bodies and axon terminals of midbrain
and striatal GABAergic neurons. Conclusive evidence for a6*
nAChR expression, however, is restricted to DA neuron cell
bodies and axon terminals. Our present results show that, in
midbrain, manipulating a6* nAChR sensitivity affects only DA
neurons (Figures S11, 8B, and 8D), whereas sensitized a4* re-
ceptors simultaneously increase the sensitivity of DA neurons
and their inhibitory GABAergic inputs (Figures 6, 8A, and 8C).
This circuit-level difference explains a distinction between the
locomotor effects of nicotine in the two gain-of-function mouse
strains. WT mice display a hypolocomotor response to nicotine,
anda4L9
0A mice recapitulate the WT response, only at much lower
doses (Tapper et al., 2007). On the other hand, a6L9
0S mice exhibit
a sign change: psychomotor stimulation by nicotine (Figure 1F).
This cell-type difference in expression between a4 and a6
nAChR subunits may also lead to the behavioral differences
between a4L9
0A and a6L9
0S mice in response to repeated nicotine
injections. Repeated, selective activation of a4* nAChRs pro-
duces locomotor sensitization (Tapper et al., 2004, 2007),
whereas repeated activation of a6* nAChRs produces neither
tolerance nor sensitization (Figure 1I). Locomotor sensitization
may require nicotinic activation of GABAergic transmission,
which is afforded by a4* nAChRs but not a6* nAChRs (Nashmi
et al., 2007). Alternatively, the mechanism of sensitization could
involve nAChR upregulation, to which a4b2* receptors are par-
ticularly prone (Nguyen et al., 2003) but to which a6* receptors
are apparently resistant (Perry et al., 2007).
a6* nAChRs Preferentially Modulate the Mesolimbic
versus Mesostriatal DA System
The VTA and NAc (mesolimbic DA pathway) are key mediators of
the addictive properties of nicotine (Corrigall et al., 1994), and
a recent report using pharmacological blockade suggests that
a6* nAChRs specifically mediate cholinergic modulation of DA
release in NAc (Exley et al., 2007). Our results support this in
two ways: (1) we observe greater expression of a6* currents in
VTA versus SNc neurons (compare Figures 4E, 6D, and S8A),
and (2) DA release is more strongly controlled by a6* on VTA-
derived terminals versus SNc-derived terminals (compare EC50
values in Figures 2G and 2H). Although we cannot completely
distinguish the contribution of dorsal versus ventral striatum in
our behavioral experiments, our DA release data suggest that
the first a6* nAChRs significantly activated by nicotine are those
in the mesolimbic pathway.
VTA b2* nAChRs are critical mediators of exploratory behavior
in mice (Granon et al., 2003; Maskos et al., 2005). The VTA is
Figure 8. Hypersensitive DA Neurons Alter
Basal Ganglia Circuitry for Cholinergic
Transmission and Responses to Nicotine
(A–D) Schematic for baseline and nicotine-
induced activation of DA neurons. In WT mice,
background (A) ACh weakly stimulates somatic
and presynaptic a4* and a6* nAChRs, leading to
tonic DA release in ST. In a6L9
0S mice, baseline
ACh (B) activation of a6* nAChRs may cause
heightened DA release via increased somatic
and presynaptic nAChR activity. In WT (C), sys-
temic nicotine (R0.5 mg/kg, i.p.) activates a4*
and a6* nAChRs on DA neurons, and a4* nAChRs
on GABA neurons/terminals in midbrain. This,
coupled with activation of presynaptic a4* and
a6* nAChRs, increases DA release in ST. In
a6L9
0S mice (D), systemic nicotine (%0.15 mg/kg,
i.p.) specifically activates somatic and presynaptic
a6* nAChRs on DA neurons without activating a4*
nAChRs on inhibitory GABAergic inputs, which
strongly stimulates DA release.Neuron 60, 123–136, October 9, 2008 ª2008 Elsevier Inc. 133
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nAChRs and Cholinergic Control of DA Releaseimportant for curiosity or the response to novelty, perhaps by re-
sponding to cholinergic excitation to mediate the switch to burst
firing in DA neurons. If VTA b2* nAChRs are necessary for normal
responses to novelty, then it is not surprising that sensitized VTA
b2* nAChRs such as a6L9
0Sb2* in mutant mice render the animals
hypersensitive to novelty (Figures 1C and 1D). This phenotype is
much smaller or absent in a4L9
0A mice, reflecting the relative
importance of selectively activating DA in eliciting this response.
a6L9
0S Mice Reveal a Role for Cholinergic Transmission
in Behavioral Hyperactivity
In midbrain, ACh released from mesopontine cholinergic termi-
nals acts on DA neuron nAChRs in vivo (Mameli-Engvall et al.,
2006) (Figure 8A). a6* nAChRs have the highest known sensitivity
to ACh, making them excellent candidates to mediate the stim-
ulatory action of endogenous ACh on DA neurons. The tonic ac-
tivation of a6* nAChRs that we observe in midbrain slices is likely
due to endogenous ACh. Although we observe no difference in
DA neuron baseline firing in vitro (Figures 4I and S8B), tonic mid-
brain a6* nAChR activation may be sufficient in vivo to contribute
to behavioral phenotypes in a6L9
0S mice. In striatum, tonic extra-
cellular DA is controlled by presynaptic nAChRs via continuous,
low-level ACh released from cholinergic interneurons (Zhou
et al., 2001). This acts to maintain a high probability of DA release
from the terminal during tonic firing (Rice and Cragg, 2004;
Zhang and Sulzer, 2004). Sensitization of a6* nAChRs (in a6L9
0S
mice) likely modifies DA release at presynaptic terminals in addi-
tion to effects at DA neuron cell bodies; DA terminals with a6L9
0S
channels presumably have a decreased failure rate for single
spike-induced release. This is supported by in vitro electrochem-
ical studies of a6*-dependent DA release (Exley et al., 2007).
Thus, genetic sensitization of DA neurons to ACh in midbrain
and facilitation of DA release in striatum (Figure 8B) could easily
account for the home cage hyperactivity and the sustained hy-
peractivity of a6L9
0S mutant mice when placed in a novel environ-
ment. These phenotypes are reminiscent of DA transporter
knockdown mice, which also show hyperactivity and impaired
response habituation (Zhuang et al., 2001). Although a6*-regu-
lated norepinephrine (NE) release does not contribute to nicotine
psychomotor activation (Figure 1H), our results do not rule out
a role for NE in a6L9
0S spontaneous hyperactivity. Future studies
on the mechanisms of a6L9
0S mouse hyperactivity could be use-
ful in understanding the causes of human hyperactivity, such as
that observed in ADHD.
In a6L9
0S mice, low-dose nicotine stimulates psychomotor
activation similar to amphetamine in WT animals (Figure 1E). Nic-
otine thus recapitulates the spontaneous hyperactivity we ob-
serve, though with different kinetics. The difference in response
magnitude and duration between responses to novelty and
responses to nicotine may reflect different agonist concentration
and desensitization kinetics. After ACh is released from nerve
terminals, it is hydrolyzed by acetylcholinesterase (AChE), which
has a turnover rate of 104/s (Wathey et al., 1979) and is abundant
in DAergic areas. ACh may not reach concentrations, or remain
long enough, to significantly desensitize a6* nAChRs, perhaps
even those with mutant L90S subunits. In contrast, nicotine is
eliminated with a half-life of 7 min (Matta et al., 2007)—nearly
107 times longer—and can therefore desensitize receptors, es-134 Neuron 60, 123–136, October 9, 2008 ª2008 Elsevier Inc.pecially b2* nAChRs (Mansvelder et al., 2002). Bolus injections
of nicotine in a6L9
0S mice potently activate mutant receptors,
and the locomotor response decay kinetics could therefore be
dominated by both receptor desensitization and metabolic
breakdown of nicotine.
Therapeutic Targeting of DA Disorders with a6* nAChRs
The cholinergic system is targeted by several drugs used to treat
neural disorders such as Alzheimer’s disease and Parkinson’s
disease (PD). There is a well-documented inverse correlation be-
tween smoking and PD (Ritz et al., 2007), and other disorders
that can be treated with DA drugs (ADHD, schizophrenia) are as-
sociated with a high incidence of smoking (de Leon et al., 1995;
Pomerleau et al., 1995). These findings suggest the important
role played by the cholinergic system in DA transmission. Our re-
sults show that a sensitized response in DA neurons to endoge-
nous ACh may cause a behaviorally relevant state of excess DA.
Manipulations to decrease a6* nAChR function may, therefore,
be a useful treatment for human disorders involving excess
DA. This could be in the form of a competitive antagonist or via
viral gene therapy designed to eliminate a6* activity. On the other
hand, patients with PD (low DA) may be aided by a6* agonists or
allosteric modulators to augment DA release from residual DA
terminals (Quik and McIntosh, 2006). Our data clearly show
that an a6-selective compound potently stimulates both DA
release and locomotor activity (Figure 3). Further, the absence
of sensitization or tolerance to repeated a6* activation (Figure 1I)
suggests that clinical a6* agonists may have reduced abuse lia-
bility. Unlike L-DOPA or direct DA receptor agonists/antagonists,
compounds manipulating DA neuron firing by targeting a6*
nAChRs might avoid well known use-dependent side effects
such as dyskinesias.
EXPERIMENTAL PROCEDURES
Bacterial Artificial Chromosome Recombineering and Transgenesis
For a complete description of the methods used for recombineering and trans-
genesis, see Supplemental Data. A bacterial artificial chromosome (BAC),
RP24-149I12, containing the mouse a6 nicotinic receptor subunit gene
(Chrna6) was obtained from the BACPAC Resource Center (BPRC) at Chil-
dren’s Hospital Oakland Research Institute (Oakland, CA). BAC recombineer-
ing was carried out using a Counter Selection BAC modification kit (Gene-
bridges; Heidelberg, Germany). a6 nAChR Leucine 280 (Leu90) was mutated
to a serine using a two-step selection/counterselection protocol. First, a 15 bp
stretch of Chrna6 exon 5 containing the coding sequence for V278 through
L282 was replaced with a cassette containing a tandem selection (neo)/coun-
terselection (rpsL) marker. Neo was used to select positive recombinants, and
an engineered NotI restriction site pair flanking the selection cassette was
used to confirm the location of the exogenously inserted DNA within the
BAC. In the second step, Chrna6 exon 5 was restored using counterselection.
Bacterial cells were placed under selective pressure (via streptomycin sensi-
tivity gained by insertion of the rpsL marker) to lose the neo-rpsL cassette
and replace it with nonselectable DNA engineered to insert the Leu90 to Ser
(L280S) mutation. The resultant strain harbored a BAC with no ectopic DNA
in or around Chrna6.
Injection-grade a6L9
0S BAC DNA was prepared via double CsCl banding
(Lofstrand Labs; Gaithersberg, MD). To produce transgenic animals, BAC
DNA was injected into the male pronucleus of recently fertilized FVB/N
embryos and implanted into pseudopregnant Swiss-Webster surrogates.
Transgenic founders were identified using tail biopsy DNA and PCR primers
designed to detect the L90S mutation. Founders were crossed to C57BL/6J
Neuron
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nAChRs and Cholinergic Control of DA Release(Jackson Labs; Bar Harbor, ME) to obtain germline transmission and to estab-
lish a colony, and transgenic mice were continually backcrossed to C57BL/6J.
Locomotor Activity
Locomotor activity was assayed similar to Fonck et al. (2005) and is described
in Supplemental Data.
Neurotransmitter Release from Striatal Synaptosomes
DA and GABA release from striatal synaptosomes was carried out similar to
Grady et al. (2002) and Nashmi et al. (2007) and is described in Supplemental
Data.
Patch-Clamp Electrophysiology
Methods for patch-clamp recordings are completely detailed in Supplemental
Data. Transgenic and nontransgenic mice (midbrain, P17–P25; locus coeru-
leus, P21–P28; striatum, P42–P56) were anesthetized, followed by cardiac
perfusion with oxygenated (95% O2/5% CO2) ice-cold glycerol-based artificial
CSF (gACSF). Coronal slices (midbrain, striatum: 250 mm; pons: 200 mm) were
cut and allowed to recover for at least 1 hr at 32C in regular, oxygenated
artificial CSF (ACSF). Somatic recordings from visually identified midbrain,
pontine, or striatal neurons were obtained using patch electrodes filled with in-
ternal pipette solution containing 135 mM potassium gluconate, 5 mM EGTA,
0.5 mM CaCl2, 2 mM MgCl2, 10 mM HEPES, 2 mM Mg-ATP, and 0.1 mM GTP.
Recordings were taken at 32C with an Axopatch 1D amplifier, a 16 bit Digi-
data 1322A A/D converter, and pCLAMP9.2 software (all Molecular Devices
Axon; Sunnyvale, CA). For nicotine application, a drug-filled micropipette
was used to locally apply nicotine using pressure application. A piezoelectric
translator rapidly moved the nicotine-filled pipette close to and away from
the cell to avoid nAChR desensitization.
Immunohistochemistry and Spectral Confocal Imaging
Coronal brain slices cut for patch-clamp recording were processed similar to
Lerchner et al. (2007) and stained according to Drenan et al. (2005). Spectral
confocal imaging was similar to Drenan et al. (2008). See Supplemental Data
for more details.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures,
Figures, and Tables and can be found with this article online at http://www.
neuron.org/supplemental/S0896-6273(08)00756-3.
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